Canada Markets close in 4 hrs 44 mins

Therapix Biosciences, Cannabis Based Drug Candidates Pipeline Review

NEW YORK, NY / ACCESSWIRE / October 5, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Therapix Biosciences Ltd. (TRPX) is a specialty clinical-stage pharmaceutical company creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals.

On October 1st, TRPX shares closed at $4.57 and have since then hit an intra-day high of $7.65 (+67%). Trading volumes have increased dramatically in the same time frame.

The TRPX products and how they differ from other cannabis-based treatments READ MORE

Copy and paste to your browser may be required to view the report -

The cannabinoid system is prone to "entourage effect", whether THC being potentiated by other cannabinoids or by terpene compounds. Therapix's leading entourage compound is PEA. Combining PEA with THC may stimulate cannabinoid receptors, inhibit metabolic degradation, and thus increase uptake of THC.

Get the clinical trial updates and pipeline review here READ MORE

Copy and paste to your browser may be required to view the report -

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE: Traders News Source